AstraZeneca :Dato-DXd Fails To Significantly Improve Overall Survival In Phase III Lung Cancer Trial

(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) datopotamab deruxtecan (Dato-DXd) did not significantly improve overall survival for adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer, according to detailed results from https://www.nasdaq.com/articles/astrazeneca-dato-dxd-fails-significantly-improve-overall-survival-phase-iii-lung-cancer